Recommend protocols backed by evidence, not hype
Most current knowledge comes from adverse-event case reports of unregulated grey-market use rather than controlled trials
Emerging evidence indicates their potential role in the management of diverse obesity-related comorbidities, including metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, polycystic ovary syndrome, neurodegenerative disorders, and even substance use disorders
Continuous seven-day intraventricular administration of MT-II to MIA mice resulted in a significant improvement in sociability
For APOE4 carriers specificallywho show accelerated mitochondrial dysfunctionthis pathway represents a mechanistically rational intervention target
McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL